Listed by the USPTO as CHANDRA, GYAN
Tech Center 3700 • Art Units: 1646 1653 1674 3783
This examiner grants 71% of resolved cases
CHANDRA, GYAN has 1011 resolved cases, an allowance rate of 71.3%, and a median of 939 days to allowance. The profile is assigned to Tech Center 3700 and art unit 1646. The 27.5% interview lift indicates a meaningful positive measured association in a substantial record.
The listed companies are Novo Nordisk A/S, MannKind Corporation, and Kashiv Biosciences LLC, placing biotechnology and pharmaceutical work at the center of the listed portfolio. K&L Gates LLP, BIRCH STEWART KOLASCH & BIRCH, LLP, and CHALKER FLORES, LLP are the leading firms. Practitioners can use the interview measure and company concentration to shape preparation for comparable life-science matters.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | Non-Final OA | Novo Nordisk A/S |
| 18591754 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | Non-Final OA | Novo Nordisk A/S |
| 18426412 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | Non-Final OA | Novo Nordisk A/S |
| 18550920 | NOVEL FORMULATION OF FUSION PROTEIN | Non-Final OA | Kashiv BioSciences, LLC |
| 18409277 | THERAPEUTIC USES OF DULAGLUTIDE | Non-Final OA | Eli Lilly and Company |
| 18412867 | Recombinant Protein For Inducing Cytoplasmic Vacuolization Cell Death And Use Thereof | Non-Final OA | Shandong University |
| 18041825 | INSULIN RECEPTOR PARTIAL AGONISTS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18610188 | COMBINATION OF IL-4/IL-13 PATHWAY INHIBITORS AND PLASMA CELL ABALATION FOR TREATING ALLERGY | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18275855 | NON-TERMINAL ANTIBODY DISCOVERY METHODS AND SINGLE CELL ASSAYS | Non-Final OA | AMGEN INC. |
| 18430757 | THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18271173 | ENGINEERED STABLE ACE2 PROTEIN VARIANTS AS ANTIVIRAL NEBULIZED THERAPEUTICS | Final Rejection | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18024819 | PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Final Rejection | SEOUL NATIONAL UNIVERSITY HOSPITAL |
| 18122768 | A FUSION PROTEON OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) AND INTERLEUKIN-2 (IL-2) AND APPLICATIONS THEREOF | Non-Final OA | NATIONAL CHUNG HSING UNIVERSITY |
| 18360393 | POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR | Non-Final OA | Sanofi |
| 18247235 | PARTICLE BASED FORMULATION OF SARS-COV-2 RECEPTOR BINDING DOMAIN | Final Rejection | The Research Foundation for The State University of New York |
| 18334212 | Compositions and Methods for Treating Osteonecrosis | Non-Final OA | Texas Scottish Rite Hospital for Children |
| 18546578 | AQUEOUS COMPOSITION OF AN ENGINEERED PROTEIN CONSTRUCT COMPRISING AN FC DOMAIN | Non-Final OA | ARECOR LIMITED |
| 18593204 | METHOD OF TREATING DIABETES TYPE 2 BY ADMINISTERING ULTRARAPID ACTING INSULIN | Non-Final OA | MannKind Corporation |
| 18440382 | USE OF ULTRARAPID ACTING INSULIN | Non-Final OA | MannKind Corporation |
| 17862825 | METHODS AND COMPOSITIONS RELATING TO HOT-START, ONE-STEP, REVERSE TRANSCRIPTION-COUPLED PCR | Final Rejection | Wayne State University |
| 18040869 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | Non-Final OA | HANMI PHARM. CO., LTD. |
| 17797644 | METHODS FOR THE TREATMENT OF HUNTER SYNDROME | Final Rejection | DENALI THERAPEUTICS INC. |
| 18444218 | DENDRIMER COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME | Non-Final OA | Ashvattha Therapeutics, Inc. |
| 18289596 | T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 | Non-Final OA | The United States of America, as represented by the Secretary, Department of Health and Human |
| 18285668 | IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS | Final Rejection | INNATE PHARMA |
| 18274605 | METHOD AND MEANS FOR MODULATING B-CELL MEDIATED IMMUNE RESPONSES | Non-Final OA | UNIVERSITÄT ULM |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | Non-Final OA | Acceleron Pharma Inc. |
| 18217257 | Affinity Chromatography Ligands with Mild Elution pH | Non-Final OA | GUANGZHOU BINDING TECHNOLOGIES CO., LIMITED |
| 18028117 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Non-Final OA | RHYTHM PHARMACEUTICALS, INC. |
| 18028036 | TRANSDERMAL INSULIN FORMULATIONS AND METHODS OF USE THEREOF | Non-Final OA | Transdermal Delivery Solutions Corp. (d.b.a. HypoSpray Pharma) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy71.3% of resolved applications examined by Gyan Chandra were allowed (1,011 resolved cases), compared with 40.9% across Art Unit 1646 over the last five years.
This examiner's interview lift is +27.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Gyan Chandra took 939 days on average from filing to allowance.
Gyan Chandra examines applications in Art Unit 1646 in Tech Center 3700 (Medical Devices & Mechanical Engineering).
